Bioinformatics uses RNA sequencing to guide personalized drug prescription methods for stomach cancer.

This article is the original of the translational medicine network. Please indicate the source: Cathy introduction: gastric cancer is a malignant tumor originating from the gastric mucosa epithelium. Incidence rate is the highest in all kinds of malignant tumors in China.due to the change of diet structure and the increase of work pressure, the incidence of gastric cancer is younger.early gastric cancer often has no symptoms or only slight symptoms. When the clinical symptoms are obvious, the lesions are already advanced, which brings great difficulties to the treatment.recently, Russian researchers developed a personalized gastric cancer treatment technology based on RNA sequencing for the first time.immunotherapy is the latest treatment for gastric cancer. However, the response of patients to treatment is often unpredictable, so personalized therapy and drug prescription should be formulated according to the specific situation.recently, researchers from the Moscow Institute of physics and Technology (MIPT) first developed a personalized gastric cancer treatment technology based on RNA sequencing of tumor cells, bringing new ideas to the treatment of gastric cancer.the study was led by Maxim Sorokin, a senior researcher at the laboratory of translational genomics bioinformatics, Moscow Institute of physics and technology, and published in the molecular case study of lengquangang with the support of the Russian science foundation.the title "RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer" is the fifth most common cancer related mortality.due to the low proportion of early diagnosis, most patients are diagnosed as late stage.for HER2 positive cases, the first-line treatment criteria include fluorouracil and platinum compounds combined with trastuzumab.there are several alternative options for recurrent gastric cancer, including ramikumab, a monoclonal therapeutic antibody that inhibits VEGF mediated tumor angiogenesis by binding to VEGFR2, alone or in combination with other cancer drugs.however, the total response rate of ramikumab or its mixture accounted for 30% – 80% of the total number of patients, indicating that individualized drug prescriptions are needed to improve the therapeutic effect of gastric cancer. Br / >, and the clinical information of patients with advanced gastric cancer who were treated with mirex.the results showed that three genes were expressed in different degrees in tumor: chrm3, lrfn1 and tex15.the expression of chrm3 was up-regulated in the reaction.the researchers used the bioinformatics platform on cobox to simulate the efficiency of ramikumab, and compared the output model results with the actual tumor response data.the results showed that the predicted clinical results were consistent with the actual clinical results (AUC ≥ 0.7). these results suggest that RNA sequencing can be used to screen individualized prescriptions for the treatment of gastric cancer with ramicuriab, and reveal the potential molecular mechanism of resistance to ramicuriab. recurrent gastric tumors are treated with therapeutic antibodies that block cell surface receptors responsible for receiving growth promoting signals. without them, cell division would stop and the tumor size would not increase. in cancer treatment, it is particularly important to prevent the growth of blood vessels, which provide nutrition and oxygen for tumors. ramikumab is a therapeutic antibody used to destroy the growth of blood vessels in tumor tissues. but the efficacy of the drug varies from person to person. previously, MIPT bioinformatics experts, medical research center and industry experts suggested that the data of patients' cancer gene expression level could be used to evaluate the efficacy of ramikumab in different situations. the first author of the study, Maxim Sorokin, senior researcher of MIPT translational genomics bioinformatics laboratory and director of oncobox bioinformatics department, said: "this study is actually the first case of successfully prescribing [ramiku] for gastric cancer patients, which is not random, but based on our molecular marker analysis based on RNA sequencing tracking. "combined with information technology, modern molecular biology methods enable researchers to collect qualitative data on the expression of each gene in a cell. by analyzing these data, we can find the key to diagnose tumor disease and predict its therapeutic effect. Ref.: [1] Maxim Sorokin et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer, Molecular case studies (2020). Doi: 10.1101/mcs.a004945 [2] [3] [4] recommended reading: fighting the epidemic situation, translational medicine network content team series report: [Nature] heavyweight: a single designed DNA drug treatment is expected to completely cure Parkinson's disease! Turn to share: Salon of single cell sequencing technology application [major breakthrough] China's first new coronal mRNA vaccine approved to start clinical trial [Nature sub journal] liquid biopsy can accurately detect early renal cancer